Table 2 Subgroup analysis of ORR and R0 resection

ORR

8

1.24

1.13, 1.37

 < 0.001

52%

0.03

RAS/KRAS wild type

8

1.20

1.02, 1.41

0.03

81%

 < 0.001

KRAS mutant

4

0.99

0.78, 1.25

0.94

64%

0.04

Cetuximab

6

1.28

1.13, 1.45

 < 0.001

58%

0.04

Panitumumab

2

1.18

0.98, 1.42

0.08

55%

0.11

R0 resection

8

1.63

1.27, 2.09

 < 0.001

0

0.48

RAS/KRAS wild type

8

1.60

1.17, 2.20

0.003

23%

0.25

KRAS mutant

2

2.90

0.46, 18.54

0.26

18%

0.27

Cetuximab

6

1.69

1.26, 2.28

 < 0.001

0

0.50

Panitumumab

2

1.66

0.80, 3.43

0.18

48%

0.17